These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10083976)

  • 1. Synthesis and pharmacological evaluation of new (indol-3-yl)alkylamides and alkylamines acting as potential serotonin uptake inhibitors.
    Fouchard F; Menciu C; Duflos M; Le Baut G; Lambrey B; Mourgues M; Perrissoud D
    Arzneimittelforschung; 1999 Feb; 49(2):96-105. PubMed ID: 10083976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.
    Matzen L; van Amsterdam C; Rautenberg W; Greiner HE; Harting J; Seyfried CA; Böttcher H
    J Med Chem; 2000 Mar; 43(6):1149-57. PubMed ID: 10737747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New indole derivatives as potent and selective serotonin uptake inhibitors.
    Malleron JL; Guérémy C; Mignani S; Peyronel JF; Truchon A; Blanchard JC; Doble A; Laduron P; Piot O; Zundel JL
    J Med Chem; 1993 Apr; 36(9):1194-202. PubMed ID: 8487257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect.
    Wróbel MZ; Chodkowski A; Herold F; Marciniak M; Dawidowski M; Siwek A; Starowicz G; Stachowicz K; Szewczyk B; Nowak G; Belka M; Bączek T; Satała G; Bojarski AJ; Turło J
    Eur J Med Chem; 2019 Dec; 183():111736. PubMed ID: 31586817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant-like activity of VN2222, a serotonin reuptake inhibitor with high affinity at 5-HT1A receptors.
    Tordera RM; Monge A; Del Río J; Lasheras B
    Eur J Pharmacol; 2002 May; 442(1-2):63-71. PubMed ID: 12020683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotonergic activity of HP 184: does spontaneous release have a role?
    Smith CP; Woods-Kettelberger AT; Corbett R; Chesson SM; Bores GM; Petko WW; Roehr JE; Kongsamut S
    Neurochem Res; 1996 May; 21(5):575-83. PubMed ID: 8726966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New 1-aryl-3-(4-arylpiperazin-1-yl)propane derivatives, with dual action at 5-HT1A serotonin receptors and serotonin transporter, as a new class of antidepressants.
    Martínez-Esparza J; Oficialdegui AM; Pérez-Silanes S; Heras B; Orús L; Palop JA; Lasheras B; Roca J; Mourelle M; Bosch A; Del Castillo JC; Tordera R; Del Río J; Monge A
    J Med Chem; 2001 Feb; 44(3):418-28. PubMed ID: 11462981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and antidepressant activity of a series of arylalkanol and aralkyl piperazine derivatives targeting SSRI/5-HT
    Gu ZS; Xiao Y; Zhang QW; Li JQ
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5420-5423. PubMed ID: 29138029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]- 5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent.
    Bromidge SM; Dabbs S; Davies DT; Davies S; Duckworth DM; Forbes IT; Gaster LM; Ham P; Jones GE; King FD; Mulholland KR; Saunders DV; Wyman PA; Blaney FE; Clarke SE; Blackburn TP; Holland V; Kennett GA; Lightowler S; Middlemiss DN; Trail B; Riley GJ; Wood MD
    J Med Chem; 2000 Mar; 43(6):1123-34. PubMed ID: 10737744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships.
    Maryanoff BE; McComsey DF; Gardocki JF; Shank RP; Costanzo MJ; Nortey SO; Schneider CR; Setler PE
    J Med Chem; 1987 Aug; 30(8):1433-54. PubMed ID: 3039136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and activity of a new class of dual acting norepinephrine and serotonin reuptake inhibitors: 3-(1H-indol-1-yl)-3-arylpropan-1-amines.
    Mahaney PE; Vu AT; McComas CC; Zhang P; Nogle LM; Watts WL; Sarkahian A; Leventhal L; Sullivan NR; Uveges AJ; Trybulski EJ
    Bioorg Med Chem; 2006 Dec; 14(24):8455-66. PubMed ID: 16973367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical profile of YM992, a novel selective serotonin reuptake inhibitor with 5-HT2A receptor antagonistic activity.
    Hatanaka K; Nomura T; Hidaka K; Takeuchi H; Yatsugi S; Fujii M; Yamaguchi T
    Neuropharmacology; 1996; 35(11):1621-6. PubMed ID: 9025110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
    J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of 5-HT(2a) and 5-HT(2B/2C) receptors in the behavioral interactions between serotonin and catecholamine reuptake inhibitors.
    McMahon LR; Cunningham KA
    Neuropsychopharmacology; 2001 Mar; 24(3):319-29. PubMed ID: 11166521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
    Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
    J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
    Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
    J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential.
    Hertel P; Didriksen M; Pouzet B; Brennum LT; Søby KK; Larsen AK; Christoffersen CT; Ramirez T; Marcus MM; Svensson TH; Di Matteo V; Esposito E; Bang-Andersen B; Arnt J
    Eur J Pharmacol; 2007 Nov; 573(1-3):148-60. PubMed ID: 17689529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats.
    Jastrzębska-Więsek M; Siwek A; Partyka A; Antkiewicz-Michaluk L; Michaluk J; Romańska I; Kołaczkowski M; Wesołowska A
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Aug; 389(8):839-49. PubMed ID: 27106213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3-Phenyl-1-indanamines. Potential antidepressant activity and potent inhibition of dopamine, norepinephrine, and serotonin uptake.
    Bøgesø KP; Christensen AV; Hyttel J; Liljefors T
    J Med Chem; 1985 Dec; 28(12):1817-28. PubMed ID: 2999402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a 5-HT7 receptor antagonist DR4004 on the exploratory behavior in a novel environment and on brain monoamine dynamics in mice.
    Takeda H; Tsuji M; Ikoshi H; Yamada T; Masuya J; Iimori M; Matsumiya T
    Eur J Pharmacol; 2005 Jul; 518(1):30-9. PubMed ID: 16002064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.